Earli

Contract Research Associate/Senior Research Associate, Molecular Analyis

Earli  •  $40 - $50/hr  •  Redwood City, CA (Onsite)  •  16 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
40
AI Success™

Job Description

Earli is a BioAI therapeutics firm in Redwood City, California that programs cancer to turn against itself. Cancer cells become hyperlocal factories for potent immune therapies that are otherwise too toxic to be used systemically Earli AI-designs synthetic genetic switches that are intravenously injected but ONLY activate in cancer cells, using non-integrating DNA in a stealth LNP. Once activated, they force the cancer cells to produce encoded proteins – T cell engagers, cytokines, agonists – that activate the immune system to kill the cancer. The hyperlocal activation avoids on-target/off-tumor effects and drives up the therapeutic index. Instead of focusing on where the drug goes, Earli changes where the drug is produced

Who You Are

  • You share our same sense of dedication, scientific passion and entrepreneurial spirit
  • You work well in a fast-paced and extremely focused startup environment
  • You are not only smart, but clever and constantly think outside the box
  • You are able to make logical decisions in an instant when there is little time to evaluate
  • You are a natural communicator and relationship builder
  • You stay calm under high pressure and stress
  • You have the ability to multi-task in a serious way, with an extreme attention to detail
  • You become a representative of the core DNA of the company through who you are

The Position

Earli is currently seeking a highly motivated Research Associate/Senior Research Associate to join the Molecular Analysis team as a 4-month contract position The successful candidate will play a key role in the molecular analysis of the Earli platform technology by supporting efforts to process tissue samples, extract high-quality nucleic acids, and run qPCR and RT-qPCR assays.

Your Primary Responsibilities

  • Isolate nucleic acids from a wide variety of frozen tissues from animal models using manual and semi-automated methodologies.
  • Assess quality and quantify extracted DNA and RNA
  • Perform cDNA synthesis and qPCR analysis on large numbers of samples at a time (100-150).
  • Maintain detailed electronic lab notebooks and databases, documenting all experimental procedures, sample information, and results with accuracy.
  • Work closely with other research team members to coordinate sample collection, processing, analysis, and interpretation of results.

Your Required Experience, Knowledge and Skill

  • BS degree in Molecular Biology, Biochemistry, or related life sciences field with hands-on molecular biology wet lab experience with 1+ years of experience in an industry setting.
  • Hands-on experience performing nucleic acid extraction from mammalian cells and tissue samples, cDNA synthesis, and quantification using standard molecular methods.
  • Experience with organizing and managing a high volume of samples is desired.
  • Excellent organizational skills and attention to detail, with the ability to manage multiple tasks simultaneously in a fast-paced environment.
  • Effective communication and interpersonal skills, with the ability to work collaboratively in a team setting.

The base salary for this position is $40-$50/hour depending on experience.

If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.

We look forward to hearing from you!

Earli

About Earli

Earli mission is to make cancer a benign experience by turning cancer against itself.

Earli creates genetic constructs that turn on only in cancer cells and then re-program the cancer cells to produce their own therapies, to kill themselves.

Earli has been funded by Andreessen Horowitz's a16z Bio+Health Fund, Khosla Ventures, Perceptive Advisors, Sands Capital, Marc Benioff, Menlo Ventures, Accenture Ventures, Han River Partners (S Korea). Earli is based in Redwood City, California.

For decades, the vision has been dreamed about to one day “program disease cells to kill or cure themselves.” If disease cells could be taken control of, they could be forced to run “injected biologic programs” to attack themselves or activate the body’s immune system to fight the disease. Standing in the way is a fundamental unsolved questions in medicine: how to correctly distinguish healthy cells from disease cells. For cancer, many attempts have been made to “kill the bad cells while not killing the good ones.” The conventional approaches are still crude; they attack both cancers and patients, or don't produce any response at all.

Earli turns the approach to targeting cancer cells on its head. Based on original research at Stanford University and subsequent 7 years of research at Earli, the company has built programmable genetic constructs that can infiltrate any cells but use conditional logic inside the cell nucleus to determine if a cell is a cancer cell, or not. The construct switches on only in cancer cells, then forcing them to become "factories" that produce encoded proteins that activate the immune system to attack and ultimately kill the cancer. In essence, the cancer cells are forced to produce their own therapies.

Industry
Biotech & Life Sciences
Company Size
11-50 employees
Headquarters
Redwood City, California
Year Founded
2018
Website
earli.com
Social Media